Journal of International Psychiatry

Objective To analyze the effect of escitalopram on depression, brain-derived neurotrophic factor and inflammatory factor in patients with coronary heart disease. Methods According to the random number table method, 93 patients with coronary heart disease and depression after PCI were divided into 46 cases in the control group and 47 cases in the observation group. The patients in the control group were given psychological intervention. Oral treatment of phthalopram. Observe the changes of depression, brain-derived neurotrophic factor and serum inflammatory factor levels in the two groups after treatment, and compare the incidence of adverse events between the two groups of patients. Results After 7 days and 14 days of treatment, the HAMD score of the observation group was lower than that of the control group (P<0.05). After 8 weeks of treatment, the levels of hs-CRP, MPO and IL-18 in the observation group were lower than those in the control group, and the levels of LP and BDNF were higher than those in the observation group (P<0.05). The incidence of adverse events in the observation group was lower than that in the control group (P<0.05). Conclusion Escitalopram can improve neurotrophic factor and inflammatory factor levels in patients with depression after coronary heart disease after PCI, eliminate depression and reduce cardiovascular adverse events.

Escitalopram; Coronary heart disease; PCI; Depression; Inflammatory factors; Brain-derived neurotrophic factor; Adverse events